Home › All Companies › ARWR

ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-04-24

Key Insights

  • Chief Medical Officer James Hamilton executed a pre-planned stock sale of 10,000 shares at $75.00-$75.13 per share on April 23, 2026, pursuant to a Rule 10b5-1 trading plan, indicating a disciplined divestment strategy rather than opportunistic selling.
  • Hamilton retains 226,958 shares of beneficial ownership following the transaction, representing substantial continued investment in the company and confidence in long-term prospects despite the near-term sale.
  • The use of a 10b5-1 trading plan demonstrates compliance with insider trading regulations and suggests the sale was predetermined rather than based on material non-public information, limiting negative inference for investors.
Sentiment: Neutral Significance: 3/10
View Original Filing →
Insider Trading Filed: 2026-04-24

Key Insights

  • CFO Daniel Joseph Apel executed three separate stock sales totaling 13,095 shares on 04/22/2026 through a Rule 10b5-1 trading plan, with sales prices ranging from $69.50 to $71.97, suggesting pre-planned, systematic diversification rather than sudden confidence loss.
  • The sales appear to be tax-related, as shares were sold to satisfy tax withholding obligations on vesting restricted stock units (RSUs), which is a routine insider transaction pattern rather than a bearish signal about company prospects.
  • Apel retained 162,905 shares of beneficial ownership following these sales, maintaining substantial equity stake in ARWR and indicating continued confidence in the company despite the diversification activity.
  • The use of a 10b5-1 trading plan demonstrates compliance with insider trading regulations and suggests the transactions were executed according to a predetermined schedule rather than based on non-public information or market timing concerns.
Sentiment: Neutral Significance: 3/10
View Original Filing →
Current Report Filed: 2026-03-20

Key Insights

  • Arrowhead Pharmaceuticals held its 2026 Annual Meeting, where key proposals were approved by shareholders, including the election of directors and the adoption of an amended incentive plan.
  • The 'Say-on-Pay' proposal for executive compensation was rejected by shareholders, indicating potential concerns over the company's executive pay practices.
  • The company maintained its independent auditor, KPMG LLP, for the 2026 fiscal year, suggesting continuity in financial reporting and oversight.
Sentiment: Neutral Significance: 5/10
View Original Filing →
Current Report Filed: 2026-02-05

Key Insights

  • Arrowhead Pharmaceuticals reported its fiscal 2026 financial results, with details on its operations and performance over the period ended December 31, 2025.
  • The company did not provide any information on new material agreements, leadership changes, or earnings surprises in this 8-K filing.
  • As this appears to be a routine quarterly earnings report, the significance and potential impact on the stock is relatively low.
Sentiment: Neutral Significance: 3/10
View Original Filing →
Quarterly Report Filed: 2026-02-05

Key Insights

  • Arrowhead Pharmaceuticals reported a significant increase in revenue and net income for the quarter ended December 31, 2025, suggesting strong growth in its core business.
  • The company announced several new collaboration agreements with major pharmaceutical partners, indicating expanding opportunities in its drug pipeline.
  • Insider selling activity increased during the quarter, which may raise concerns about management's confidence in the company's near-term prospects.
Sentiment: Positive Significance: 7/10
View Original Filing →
Current Report Filed: 2026-01-12

Key Insights

  • Arrowhead Pharmaceuticals issued $700 million in convertible senior notes due in 2032, which can be converted into the company's common stock at an initial price of $87.07 per share.
  • The notes do not bear regular interest, but special interest may accrue up to 0.50% per annum if the company fails to file certain SEC reports.
  • The notes are redeemable at the company's option starting in January 2029, but only if the stock price exceeds 130% of the conversion price for a specified period.
Sentiment: Positive Significance: 7/10
View Original Filing →
Current Report Filed: 2026-01-09

Key Insights

  • Arrowhead Pharmaceuticals raised $216.6 million through a public offering of common stock and pre-funded warrants, which will provide additional capital to fund their operations and development programs.
  • The company also raised $681.3 million through the issuance of $700 million in convertible senior notes due 2032, which will further strengthen their balance sheet and financial flexibility.
  • The timing of these capital raises suggests that Arrowhead Pharmaceuticals may have significant growth opportunities and potential upcoming milestones that require additional funding.
Sentiment: Positive Significance: 8/10
View Original Filing →
Insider Trading Filed: 2026-01-08

Key Insights

  • The reporting person, Patrick O'Brien, is the Chief Operating Officer of Arrowhead Pharmaceuticals, Inc. and is conducting transactions in the company's common stock.
  • O'Brien made multiple gifts of Arrowhead Pharmaceuticals stock, totaling 2,500 shares, to relatives on January 6, 2026.
  • Additionally, O'Brien was granted 75,000 restricted stock units, which will vest in four equal annual installments, further increasing his beneficial ownership of Arrowhead Pharmaceuticals stock.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-01-08

Key Insights

  • Daniel Joseph Apel, the Chief Financial Officer of Arrowhead Pharmaceuticals, Inc. (ARWR), acquired 75,000 shares of the company's common stock on January 6, 2026, potentially signaling his confidence in the company's future performance.
  • The acquisition of shares by a key executive officer could be viewed positively by investors as it aligns his interests with those of the shareholders.
  • The reported transaction represents a 74.5% increase in Apel's direct beneficial ownership of ARWR, which may indicate his belief in the company's growth prospects.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-01-08

Key Insights

  • James C. Hamilton, the Chief Medical Officer of Arrowhead Pharmaceuticals, acquired 75,000 shares of the company's common stock through restricted stock units that will vest over four years.
  • This transaction indicates Hamilton's continued commitment to the company and confidence in its future prospects.
  • The reported transaction is a typical equity-based compensation for a senior executive and does not suggest any significant changes in the company's operations or financial performance.
Sentiment: Positive Significance: 4/10
View Original Filing →
Current Report Filed: 2026-01-06

Key Insights

  • Arrowhead Pharmaceuticals reported positive interim results from Phase 1/2a clinical trials of two of its investigational RNA interference (RNAi) therapeutics, ARO-INHBE and ARO-ALK7, for the treatment of obesity.
  • ARO-INHBE demonstrated dose-dependent reductions in serum Activin E, as well as improvements in body composition including visceral fat reduction, liver fat reduction, and increased lean tissue.
  • ARO-ALK7 showed the first RNAi-therapeutic to demonstrate adipocyte gene target silencing in a clinical trial, with rapid dose-dependent reductions in mean visceral fat.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2025-12-30

Key Insights

  • The reporting person, Mauro Ferrari, is a director of Arrowhead Pharmaceuticals, Inc. (ARWR) and has sold 7,530 shares of the company's common stock pursuant to a 10b5-1 trading plan.
  • The reporting person still holds a significant number of shares (69,053) following the reported transaction, indicating continued investment in the company.
  • The sale of shares was executed at a price of $70 per share, which may provide insight into the current market valuation of the company's stock.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Insider Trading Filed: 2025-12-30

Key Insights

  • The CEO Christopher Anzalone exercised 35,181 and 16,545 stock options, and subsequently sold 35,181 and 16,545 shares, indicating his confidence in the company's performance.
  • The options were exercised and sold pursuant to a 10b5-1 trading plan, suggesting pre-planned and structured insider transactions.
  • The CEO's remaining beneficial ownership of 3,805,926 shares demonstrates his substantial stake and alignment with shareholder interests.
Sentiment: Positive Significance: 6/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.